BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38287874)

  • 1. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.
    Zhang X; Liao X; Wang M; Liu J; Han J; An D; Zheng T; Wang X; Cheng H; Liu P
    Cancer Sci; 2024 Apr; 115(4):1170-1183. PubMed ID: 38287874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZDHHC12-mediated claudin-3
    Yuan M; Chen X; Sun Y; Jiang L; Xia Z; Ye K; Jiang H; Yang B; Ying M; Cao J; He Q
    Acta Pharm Sin B; 2020 Aug; 10(8):1426-1439. PubMed ID: 32963941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypomethylation-induced prognostic marker zinc finger DHHC-type palmitoyltransferase 12 contributes to glioblastoma progression.
    Lu F; Shen SH; Wu S; Zheng P; Lin K; Liao J; Jiang X; Zeng G; Wei D
    Ann Transl Med; 2022 Mar; 10(6):334. PubMed ID: 35434031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.
    Lund RJ; Huhtinen K; Salmi J; Rantala J; Nguyen EV; Moulder R; Goodlett DR; Lahesmaa R; Carpén O
    Sci Rep; 2017 May; 7(1):1469. PubMed ID: 28473707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells.
    Abdalbari FH; Martinez-Jaramillo E; Forgie BN; Tran E; Zorychta E; Goyeneche AA; Sabri S; Telleria CM
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
    Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
    Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting LTA4H facilitates the reshaping of the immune microenvironment mediated by CCL5 and sensitizes ovarian cancer to Cisplatin.
    Guo Z; Huang J; Huo X; Huang C; Yu X; Sun Y; Li Y; He T; Guo H; Yang J; Xue L
    Sci China Life Sci; 2024 Jun; 67(6):1226-1241. PubMed ID: 38300441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
    Noriega-Rivera R; Rivera-Serrano M; Rabelo-Fernandez RJ; Pérez-Santiago J; Valiyeva F; Vivas-Mejía PE
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells.
    Kleih M; Böpple K; Dong M; Gaißler A; Heine S; Olayioye MA; Aulitzky WE; Essmann F
    Cell Death Dis; 2019 Nov; 10(11):851. PubMed ID: 31699970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.
    Bhattacharyya S; Saha S; Giri K; Lanza IR; Nair KS; Jennings NB; Rodriguez-Aguayo C; Lopez-Berestein G; Basal E; Weaver AL; Visscher DW; Cliby W; Sood AK; Bhattacharya R; Mukherjee P
    PLoS One; 2013; 8(11):e79167. PubMed ID: 24236104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer.
    Koc ZC; Sollars VE; Bou Zgheib N; Rankin GO; Koc EC
    Front Oncol; 2023; 13():1129352. PubMed ID: 36937395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.
    Hawkins SM; Nephew KP
    Cancer Res; 2022 Dec; 82(24):4511-4512. PubMed ID: 36524345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
    Sun C; Guo E; Zhou B; Shan W; Huang J; Weng D; Wu P; Wang C; Wang S; Zhang W; Gao Q; Xu X; Wang B; Hu J; Ma D; Chen G
    BMC Cancer; 2019 Nov; 19(1):1061. PubMed ID: 31703584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
    Zhang YL; Xia XK; Zhang M
    Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
    [No Abstract]   [Full Text] [Related]  

  • 18. The Impact of Mitochondria in Ovarian Cancer Cell Metabolism, Proliferation, and Metastasis.
    Schatten H
    Adv Exp Med Biol; 2024; 1452():119-125. PubMed ID: 38805128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer.
    Criscuolo D; Avolio R; Parri M; Romano S; Chiarugi P; Matassa DS; Esposito F
    Antioxidants (Basel); 2022 Aug; 11(8):. PubMed ID: 36009263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.